A Review of Butyrylcholinesterase as a Therapeutic Target in the Treatment of Alzheimer’s Disease | Zendy

Agneta Nordberg | Zendy; Clive Ballard | Zendy; Roger Bullock | Zendy; Taher DarrehShori | Zendy; Monique Somogyi | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

A Review of Butyrylcholinesterase as a Therapeutic Target in the Treatment of Alzheimer’s Disease

Author(s) -

Agneta Nordberg,

Clive Ballard,

Roger Bullock,

Taher DarrehShori,

Monique Somogyi

Publication year - 2013

Publication title -

the primary care companion for cns disorders

Language(s) - English

Resource type - Journals

eISSN - 2155-7772

pISSN - 2155-7780

DOI - 10.4088/pcc.12r01412

Subject(s) - butyrylcholinesterase , acetylcholinesterase , rivastigmine , cholinergic , cholinesterase , acetylcholine , medicine , disease , aché , pharmacology , bioinformatics , psychology , donepezil , dementia , biology , enzyme , biochemistry

To examine the role of butyrylcholinesterase (BuChE) in cholinergic signaling and neurologic conditions, such as Alzheimer's disease (AD). The rationale for inhibiting cholinesterases in the management of AD, including clinical evidence supporting use of the dual acetylcholinesterase (AChE) and BuChE inhibitor rivastigmine, is discussed.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research